SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-14
👔
Oncotelic Therapeutics, Inc.
@OTLC_InsiderForm 4 Filing: Trieu Vuong Acquires (Grant) shares of $OTLC
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
Oncotelic Therapeutics, Inc.
Ticker: $OTLC
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-07-10
Shares: 2,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Trieu Vuong, holds the title of CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc..
On 2026-07-10, the insider transacted 2,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Trieu Vuong (CHAIRMAN AND CEO) was granted $0 of $OTLC
Post-Transaction Position: 2,000 shares
SEC Accession No: 0001493152-26-033166 (CIK: 1587074)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.